MADISON, Wis.--(BUSINESS WIRE)--ProCertus BioPharm, Inc., an oncology-based pharmaceutical company developing therapeutics to protect cancer patients against the side effects of chemotherapy and radiotherapy, has closed on a Series A Preferred Stock financing led by Venture Investors LLC (VI). VI was joined in the financing by existing investors, including Novartis Venture Fund (NVF).
